A lack of consensus guidelines or a belief that current evidence does not support such guidelines might be justified if a clinician expresses a commitment to patient-centered care and shared decision making.
AMA J Ethics. 2018;20(11):E1007-1016. doi:
10.1001/amajethics.2018.1007.
Elizabeth A. Sonntag, MD, Keyur B. Shah, MD, and Jason N. Katz, MD
Devices alter heart failure etiology, and specialists must navigate more ethical complexity than ever. How should curricula evolve to help them respond?
AMA J Ethics. 2019;21(5):E407-415. doi:
10.1001/amajethics.2019.407.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.